Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
AACR Meeting Highlights
Peptide-Based CoVac-1 Vaccine Shows Promise Against COVID-19 in Patients with Cancer
By
Phoebe Starr
AACR Meeting Highlights
June 2022, Vol 13, No 3
A team of researchers in Germany has developed a multipeptide COVID-19 vaccine that boosts immunity in immunocompromised patients, according to results of a phase 1/2 trial reported at the 2022 American Association for Cancer Research annual meeting.
Read Article
Neoadjuvant Chemoimmunotherapy May Be New Standard of Care for Patients with Resectable NSCLC
By
Phoebe Starr
AACR Meeting Highlights
June 2022, Vol 13, No 3
The phase 3 CheckMate-816 trial establishes a new standard of care for resectable non–small-cell lung cancer (NSCLC): neoadjuvant nivolumab (Opdivo) plus chemotherapy.
Read Article
Tebentafusp Extends Survival in Patients with Metastatic Uveal Melanoma
By
Phoebe Starr
AACR Meeting Highlights
June 2021, Vol 12, No 3
Treatment with tebentafusp (IMCgp100), a novel bispecific T-cell receptor (TCR) fusion protein, extended survival in patients with metastatic uveal melanoma, according to the results from a recent phase 3 trial.
Read Article
Selpercatinib Demonstrates Promising Activity in a Variety of RET Fusion–Positive Solid Tumor Types
By
Phoebe Starr
AACR Meeting Highlights
June 2021, Vol 12, No 3
Selpercatinib (Retevmo) demonstrated antitumor activity in
RET
fusion–positive tumors other than lung cancer and thyroid cancer, according to interim results from the phase 1/2 LIBRETTO-001 clinical trial. Results from the trial were presented by Vivek Subbiah, MD, Medical Director, Clinical Center for Targeted Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, at the 2021 virtual American Association for Cancer Research annual meeting.
Read Article
Why Is COVID-19 More Aggressive in Certain Patients with Cancer?
By
Phoebe Starr
AACR Meeting Highlights
,
COVID-19
June 2020, Vol 11, No 3
At the 2020 virtual American Association for Cancer Research (AACR) annual meeting, part I, a team of oncologists from different COVID-19 hotspots around the world gave a snapshot of wisdom gleaned from their experience thus far. Understanding of COVID-19 is rapidly evolving; the summaries below represent the experience as of late April 2020.
Read Article
Bispecific CAR T-Cells Show Promise in Children and Young Adults with Relapsed B-Cell ALL
By
Wayne Kuznar
AACR Meeting Highlights
June 2020, Vol 11, No 3
A bispecific chimeric antigen receptor (CAR) T-cell product directed against CD19 and CD22 antigens induced a complete response (CR) in 5 of 12 (42%) evaluable children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL).
Read Article
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
By
Phoebe Starr
AACR Meeting Highlights
June 2020, Vol 11, No 3
The addition of the checkpoint inhibitor atezolizumab (Tecentriq) to the 2 targeted therapies—the BRAF inhibitor vemurafenib (Zelboraf) and the MEK inhibitor cobimetinib (Cotellic)—improved progression-free survival (PFS) and the duration of responses compared with the 2 targeted therapies plus placebo in patients with newly diagnosed advanced melanoma and
BRAF
V600E/K mutation, according to the phase 3 IMspire150 clinical trial.
Read Article
Two Ways to Target Tumors with KRAS Mutations
By
Wayne Kuznar
AACR Meeting Highlights
June 2020, Vol 11, No 3
Tumors with
KRAS
mutation are notoriously difficult to treat. Early data presented at the 2020 American Association for Cancer Research virtual annual meeting suggest 2 new routes for the treatment of cancers with
KRAS
mutation, including (1) the combination of a RAF/MEK inhibitor and a FAK inhibitor, and (2) the use of onvansertib, an investigational competitive inhibitor of the PLK1 enzyme, together with chemotherapy.
Read Article
ctDNA Potential Biomarker for MRD Positivity and Relapse After Surgery in Patients with NSCLC
By
Phoebe Starr
AACR Meeting Highlights
June 2020, Vol 11, No 3
Data from the TRACERx lung study suggest that circulating tumor DNA (ctDNA) may be a biomarker for the detection of postsurgical minimal residual disease (MRD) in patients with non–small-cell lung cancer (NSCLC), suggesting which patients are at increased risk for disease relapse and will require more aggressive adjuvant therapy.
Read Article
Pembrolizumab Elicits High Response in Merkel-Cell Carcinoma
By
Wayne Kuznar
AACR Meeting Highlights
May 2016, Vol 7, No 4
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
William King
2.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma